Icotrokinra

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Durability of response to Icotrokinra in the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials: a potential new novel oral treatment for psoriasis.

Durability of response to Icotrokinra in the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials: a potential new novel oral treatment for psoriasis.

Journal: The British journal of dermatology

Published: July 31, 2026

Icotrokinra (Icotyde) for psoriasis.

Icotrokinra (Icotyde) for psoriasis.

Journal: The Medical letter on drugs and therapeutics

Published: July 24, 2026

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Journal: Dermatology and therapy

Published: June 24, 2026

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.

Journal: The Journal of dermatology

Published: June 14, 2026

The Efficacy of Oral Icotrokinra versus Injectable IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Comparative Meta-Analysis.

The Efficacy of Oral Icotrokinra versus Injectable IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Comparative Meta-Analysis.

Journal: Journal of the American Academy of Dermatology

Published: April 30, 2026

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.

Journal: Dermatology and therapy

Published: April 29, 2026

Editor's Highlights-June 2026.

Editor's Highlights-June 2026.

Journal: International journal of dermatology

Published: April 21, 2026

Icotrokinra: First Approval.

Icotrokinra: First Approval.

Journal: Drugs

Published: April 17, 2026

FDA approves IcotydeTM (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis.

FDA approves IcotydeTM (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis.

Journal: Annals of medicine and surgery (2012)

Published: April 02, 2026

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Journal: Journal of the American Academy of Dermatology

Published: February 24, 2026

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Journal: Journal of the American Academy of Dermatology

Published: February 20, 2026

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 13, 2026

Showing 1-12 of 30

Last Updated: 09/26/2026